Discontinued — last reported Q4 '25
TransDigm Group Acquisitions decreased by 89.7% to $93.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 16.2%, from $111.00M to $93.00M. Over 4 years (FY 2021 to FY 2025), Acquisitions shows a downward trend with a -18.8% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
cf_acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $12.00M | $0.00 | $0.00 | $422.00M | $15.00M | $10.00M | $0.00 | $740.00M | $12.00M | $14.00M | $73.00M | $1.60B | $661.00M | $29.00M | $111.00M | $99.00M | $180.00M | $907.00M | $93.00M |
| QoQ Change | — | — | -100.0% | — | — | -96.4% | -33.3% | -100.0% | — | -98.4% | +16.7% | +421.4% | >999% | -58.7% | -95.6% | +282.8% | -10.8% | +81.8% | +403.9% | -89.7% |
| YoY Change | — | — | — | — | — | +25.0% | — | — | +75.4% | -20.0% | +40.0% | — | +116.1% | >999% | +107.1% | +52.1% | -93.8% | -72.8% | >999% | -16.2% |